The U.S. actinic keratosis treatment market size is expected to reach USD 2.94 billion by 2030, expanding at a CAGR of 3.03% over the forecast period. The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.
The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.
Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.
According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.
Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp.
The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.
Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.
According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.
Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp.
U.S. Actinic Keratosis Treatment Market Report Highlights
- The surgery segment held the largest share owing to the higher demand for complete disease eradication and high penetration of cryotherapy procedures
- The photodynamic therapy segment registered the fastest growth rate because of high site specificity and less incidence of side effects
- The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease
- Based on product, the 5-fluorouracil segment dominated the U.S. actinic keratosis treatment market in 2022, whereas, the tirbanibulin segment is anticipated to be the fastest-growing segment
- The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals
- Key players dominating the market include Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A.; and Biofrontera AG
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 U.S. Actinic Keratosis Treatment Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing disease prevalence
3.2.1.2 Preventive strategies
3.2.1.3 Easy availability of treatment
3.2.2 Market restraint analysis
3.2.2.1 Lack of consumer awareness
3.2.2.2 Generic penetration
3.3 Penetration & Growth Prospect Mapping
3.4 Influenza Vaccine: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Therapy, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Therapy Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 U.S. Actinic Keratosis Treatment Market, by Therapy, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Topical/Drugs
4.5.1.1 Topical/Drugs market estimates and forecast, 2018 - 2030 (USD Million)
4.5.2 Surgery
4.5.2.1 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
4.5.2.2 Cryotherapy
4.5.2.2.1 Cryotherapy market estimates and forecast, 2018 - 2030 (USD Million)
4.5.2.3 Others
4.5.2.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
4.5.3 Photodynamic Therapy
4.5.3.1 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Product 2018 - 2030 (USD Million) (Volume, Number of Units Sold)
5.1 Definition and Scope
5.2 Product Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 U.S. Actinic Keratosis Treatment Market, by Product, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 5-fluorouracil
5.5.1.1 5-fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.1.2 Carac
5.5.1.2.1 Carac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.1.3 Fluoroplex
5.5.1.3.1 Fluoroplex market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.1.4 Actikerall
5.5.1.4.1 Actikerall market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.1.5 Tolak
5.5.1.5.1 Tolak market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.1.6 Others
5.5.1.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.2 Diclofenac
5.5.2.1 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.2.2 Solaraze
5.5.2.2.1 Solaraze market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.2.3 Voltaren
5.5.2.3.1 Voltaren market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.2.4 Pennsaid
5.5.2.4.1 Pennsaid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.2.5 Others
5.5.2.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.3 Imiquimod
5.5.3.1 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.3.2 Aldara
5.5.3.2.1 Aldara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.3.3 Zyclara
5.5.3.3.1 Zyclara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.3.4 Others
5.5.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.4 Tirbanibulin
5.5.4.1 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.5 Capecitabine
5.5.5.1 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.5.2 Xeloda
5.5.5.2.1 Xeloda market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.5.3 Others
5.5.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.6 Aminolevulinic acid
5.5.6.1 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.6.2 Ameluz
5.5.6.2.1 Ameluz market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.6.3 Levulan
5.5.6.3.1 Levulan market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.7 Porfimer sodium
5.5.7.1 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8 Others
5.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8.2 Gemzar
5.5.8.2.1 Gemzar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8.3 Clolar
5.5.8.3.1 Clolar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8.4 Vidaza
5.5.8.4.1 Vidaza market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8.5 Metvix
5.5.8.5.1 Metvix market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
5.5.8.6 Others
5.5.8.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
Chapter 6 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Drug Class Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 U.S. Actinic Keratosis Treatment Market, by Drug Class, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Nucleoside metabolic inhibitors
6.5.1.1 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
6.5.2 Nonsteroidal anti-inflammatory drugs
6.5.2.1 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
6.5.3 Immune response modifiers
6.5.3.1 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
6.5.4 Photoenhancers
6.5.4.1 Photoenhancers market estimates and forecast, 2018 - 2030 (USD Million)
6.5.5 Others
6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 U.S. Actinic Keratosis Treatment Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2022 & 2030
7.3 Segment Dashboard
7.4 U.S. Actinic Keratosis Treatment Market, by End-use, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Hospitals
7.5.1.1 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Private clinics
7.5.2.1 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3 Homecare
7.5.3.1 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Others
7.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Region, 2018 - 2030 (USD Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2022 & 2030
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 SWOT Analysis
8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
8.6.1 U.S.
8.6.1.1 U.S. actinic keratosis treatment market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.1.2 U.S.
8.6.1.2.1 Key Country Dynamics
8.6.1.2.2 Competitive Scenario
8.6.1.2.3 Regulatory Framework
8.6.1.2.4 Reimbursement Scenario
Chapter 9 U.S. Actinic Keratosis Treatment Market - Competitive Analysis
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.1.1 Ansoff matrix
9.1.2 Heat map analysis
9.1.3 Major Deals and Strategic Alliances Analysis
9.1.3.1 Joint Ventures
9.1.3.2 Licensing Agreements
9.1.3.3 Product Launches
9.1.3.1 Conferences and Campaigns
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List of key distributors and channel partners
9.3.2 Key customers
9.4 Public Companies
9.4.1 Competitive Dashboard Analysis
9.4.1.1 Market Differentiators
9.5 Private Companies
9.5.1 List of key emerging companies
9.6 Company Profiles
9.6.1 Bausch Health Companies, Inc
9.6.1.1 Company overview
9.6.1.2 Financial performance
9.6.1.3 Product benchmarking
9.6.1.4 Strategic Initiatives
9.6.2 LEO Pharma A/S
9.6.2.1 Company overview
9.6.2.2 Financial performance
9.6.2.3 Product benchmarking
9.6.2.4 Strategic Initiatives
9.6.3 Almirall, S.A
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic Initiatives
9.6.4 Biofrontera AG
9.6.4.1 Company overview
9.6.4.2 Financial performance
9.6.4.3 Product benchmarking
9.6.4.4 Strategic Initiatives
9.6.5 GALDERMA
9.6.5.1 Company overview
9.6.5.2 Financial performance
9.6.5.3 Product benchmarking
9.6.5.4 Strategic Initiatives
9.6.6 Sun Pharmaceutical Industries Ltd
9.6.6.1 Company overview
9.6.6.2 Financial performance
9.6.6.3 Product benchmarking
9.6.6.4 Strategic Initiatives
9.6.7 Novartis AG
9.6.7.1 Company overview
9.6.7.2 Financial performance
9.6.7.3 Product benchmarking
9.6.7.4 Strategic initiatives
9.6.8 Hill Dermaceuticals, Inc
9.6.8.1 Company overview
9.6.8.2 Financial performance
9.6.8.3 Product benchmarking
9.6.8.4 Strategic initiatives
9.6.9 Viatris Inc.
9.6.9.1 Company overview
9.6.9.2 Financial performance
9.6.9.3 Product benchmarking
9.6.9.4 Strategic initiatives
9.6.10 3M
9.6.10.1 Company overview
9.6.10.2 Financial performance
9.6.10.3 Product benchmarking
9.6.10.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Leading market players anticipated to witness the highest growth
Table 4 U.S. actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 6 U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
Table 7 U.S. actinic keratosis treatment market, by product, 2018 - 2030 (USD Million) (number of units sold)
Table 8 U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
Table 9 Product pipeline
Table 10 Regulatory framework
Table 11 Comparative study of brands available for diclofenac
Table 12 Comparative study of brands available for 5-Fluorouracil
Table 13 Comparative study of brands available for Imiquimod
Table 14 Treatments currently available for management of AK
Table 15 Comparative study of brands available for 5-Fluorouracil
Table 16 Comparative study of brands available for diclofenac
Table 17 Comparative study of brands available for Imiquimod
Table 18 Comparative study of brands available for Tirbanibulin
Table 19 Comparative study of brands available for Capecitabine
Table 20 Comparative study of brands available for Aminolevulinic acid
Table 21 Comparative study of brand available for Porfimer sodium
Table 22 Comparative study of brands available under others segment
Table 23 Key topical products for actinic keratosis, 2022
Table 24 Key surgical procedures for actinic keratosis, 2022
Table 25 Key photodynamic therapeutics for actinic keratosis, 2022
Table 26 Key nucleoside metabolic inhibitors for actinic keratosis
Table 27 Key NSAIDs for actinic keratosis
Table 28 Key immune response modifiers for actinic keratosis
Table 29 Key photo enhancers for actinic keratosis
Table 30 Other drug classes for actinic keratosis
Table 31 Key physician-managed treatment for actinic keratosis
Table 32 Key home-based treatment for actinic keratosis
Table 33 Leading market players anticipated to witness the highest growth
Table 34 Key companies undergoing expansions
Table 35 Key companies undertaking acquisitions
Table 36 Key companies undergoing collaborations
Table 37 Key companies launching new products/services
Table 38 Key companies undergoing other strategies
List of Figures
Fig. 1 U.S. actinic keratosis treatment market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Consumer behavior analysis
Fig. 15 Market driver relevance analysis (Current & future impact)
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 Porter’s five forces analysis
Fig. 18 PESTLE analysis
Fig. 19 U.S. actinic keratosis treatment market: Product outlook and key takeaways
Fig. 20 U.S. actinic keratosis treatment market: Product movement analysis
Fig. 21 Product segment dashboard
Fig. 22 5-Fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 23 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 24 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 25 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 26 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 27 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 28 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
Fig. 30 U.S. actinic keratosis treatment market: Therapy outlook and key takeaways
Fig. 31 U.S. actinic keratosis treatment market: Therapy movement analysis
Fig. 32 Therapy segment dashboard
Fig. 33 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S. actinic keratosis treatment market: Drug class outlook and key takeaways
Fig. 37 U.S. actinic keratosis treatment market: Drug class movement analysis
Fig. 38 Drug class segment dashboard
Fig. 39 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Photo enhancers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 U.S. actinic keratosis treatment market: End-use outlook and key takeaways
Fig. 45 U.S. actinic keratosis treatment market: End-use movement analysis
Fig. 46 End-use segment dashboard
Fig. 47 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 U.S. actinic keratosis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Ansoff Matrix
Fig. 54 Heat map analysis
Fig. 55 Market differentiators
Fig. 56 Market participant categorization
Fig. 57 U.S. actinic keratosis treatment market share analysis, 2022
Fig. 58 Strategic framework
Companies Mentioned
- Bausch Health Companies, Inc
- LEO Pharma A/S
- Almirall, S.A
- Biofrontera AG
- GALDERMA
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Hill Dermaceuticals, Inc
- Viatris Inc.
- 3M
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | January 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.39 Billion |
| Forecasted Market Value ( USD | $ 2.94 Billion |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
